TY - JOUR
T1 - Pankiller effect of prolonged exposure to menadione on glioma cells
T2 - Potentiation by vitamin C
AU - Vita, Marina F.
AU - Nagachar, Nivedita
AU - Avramidis, Dimitrios
AU - Delwar, Zahid M.
AU - Cruz, Mabel H.
AU - Siden, Åke
AU - Paulsson, Kajsa M.
AU - Yakisich, Juan Sebastian
N1 - Funding Information:
Acknowledgements This study was supported by grants from the Swedish Research Council and the Karolinska Institute. We thank Dr Peter Siesjö for providing the patient derived cells (hGCL1-8).
PY - 2011/12
Y1 - 2011/12
N2 - Menadione (Vitamin K3) has anti-tumoral effects against a wide range of cancer cells. Its potential toxicity to normal cells and narrow therapeutic range limit its use as single agent but in combination with radiation or other anti-neoplastic agents can be of therapeutic use. In this paper, we first evaluated the early (within 3 h) effect of menadione on ongoing DNA replication. In normal rat cerebral cortex mini-units menadione showed an age dependent anti-proliferative effect. In tissue mini-units prepared from newborn rats, menadione inhibited ongoing DNA replication with an IC 50 of approximately 10 μM but 50 μM had no effect on mini-units from prepared adult rat tissue. The effect of short (72 h) and prolonged exposure (1-2 weeks) to menadione alone in the DBTRG.05MG human glioma cells line and in combination with vitamin C was studied. After short period of exposure data show that menadione alone or in combination with vitamin C provided similar concentration-response curves (and IC50 values). Prolonged exposure to these drugs was evaluated by their ability to kill 100% of glioma cells and prevent regrowth when cells are re-incubated in drug-free media. In this long-term assay, menadione:vitamin C at a ratio 1:100 showed higher anti-proliferative activity when compared to each drug alone and allowed to reduce each drug concentration between 2.5 to 5-fold. Similar antiproliferative effect was demonstrated in 8 patient derived glioblastoma cell cultures. Our data should be able to encourage further advanced studies on animal models to evaluate the potential use of this combination therapy for glioma treatment.
AB - Menadione (Vitamin K3) has anti-tumoral effects against a wide range of cancer cells. Its potential toxicity to normal cells and narrow therapeutic range limit its use as single agent but in combination with radiation or other anti-neoplastic agents can be of therapeutic use. In this paper, we first evaluated the early (within 3 h) effect of menadione on ongoing DNA replication. In normal rat cerebral cortex mini-units menadione showed an age dependent anti-proliferative effect. In tissue mini-units prepared from newborn rats, menadione inhibited ongoing DNA replication with an IC 50 of approximately 10 μM but 50 μM had no effect on mini-units from prepared adult rat tissue. The effect of short (72 h) and prolonged exposure (1-2 weeks) to menadione alone in the DBTRG.05MG human glioma cells line and in combination with vitamin C was studied. After short period of exposure data show that menadione alone or in combination with vitamin C provided similar concentration-response curves (and IC50 values). Prolonged exposure to these drugs was evaluated by their ability to kill 100% of glioma cells and prevent regrowth when cells are re-incubated in drug-free media. In this long-term assay, menadione:vitamin C at a ratio 1:100 showed higher anti-proliferative activity when compared to each drug alone and allowed to reduce each drug concentration between 2.5 to 5-fold. Similar antiproliferative effect was demonstrated in 8 patient derived glioblastoma cell cultures. Our data should be able to encourage further advanced studies on animal models to evaluate the potential use of this combination therapy for glioma treatment.
UR - http://www.scopus.com/inward/record.url?scp=84856024885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856024885&partnerID=8YFLogxK
U2 - 10.1007/s10637-010-9489-0
DO - 10.1007/s10637-010-9489-0
M3 - Article
C2 - 20625795
AN - SCOPUS:84856024885
SN - 0167-6997
VL - 29
SP - 1314
EP - 1320
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 6
ER -